Literature DB >> 9834033

K+ is an endothelium-derived hyperpolarizing factor in rat arteries.

G Edwards1, K A Dora, M J Gardener, C J Garland, A H Weston.   

Abstract

In arteries, muscarinic agonists such as acetylcholine release an unidentified, endothelium-derived hyperpolarizing factor (EDHF) which is neither prostacyclin nor nitric oxide. Here we show that EDHF-induced hyperpolarization of smooth muscle and relaxation of small resistance arteries are inhibited by ouabain plus Ba2+; ouabain is a blocker of Na+/K+ ATPase and Ba2+ blocks inwardly rectifying K+ channels. Small increases in the amount of extracellular K+ mimic these effects of EDHF in a ouabain- and Ba2+-sensitive, but endothelium-independent, manner. Acetylcholine hyperpolarizes endothelial cells and increases the K+ concentration in the myoendothelial space; these effects are abolished by charbdotoxin plus apamin. Hyperpolarization of smooth muscle by EDHF is also abolished by this toxin combination, but these toxins do not affect the hyperpolarizaiton of smooth muscle by added K+. These data show that EDHF is K+ that effluxes through charybdotoxin- and apamin-sensitive K+ channels on endothelial cells. The resulting increase in myoendothelial K+ concentration hyperpolarizes and relaxes adjacent smooth-muscle cells by activating Ba2+-sensitive K+ channels and Na+/K+ ATPase. These results show that fluctuations in K+ levels originating within the blood vessel itself are important in regulating mammalian blood pressure and flow.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834033     DOI: 10.1038/24388

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  305 in total

1.  Bradykinin attenuates the [Ca(2+)](i) response to angiotensin II of renal juxtamedullary efferent arterioles via an EDHF.

Authors:  J Marchetti; F Praddaude; R Rajerison; J L Ader; F Alhenc-Gelas
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

Review 2.  Endothelium-derived free radicals: for worse and for better.

Authors:  P M Vanhoutte
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

3.  Effects of inhibitors of small- and intermediate-conductance calcium-activated potassium channels, inwardly-rectifying potassium channels and Na(+)/K(+) ATPase on EDHF relaxations in the rat hepatic artery.

Authors:  D A Andersson; P M Zygmunt; P Movahed; T L Andersson; E D Högestätt
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro.

Authors:  M H Hawthorn; C R Chapple; M Cock; R Chess-Williams
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  Suppression of K(+)-induced hyperpolarization by phenylephrine in rat mesenteric artery: relevance to studies of endothelium-derived hyperpolarizing factor.

Authors:  G R Richards; A H Weston; M P Burnham; M Félétou; P M Vanhoutte; G Edwards
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 6.  Lipids and endothelium-dependent vasodilation--a review.

Authors:  Lars Lind
Journal:  Lipids       Date:  2002-01       Impact factor: 1.880

7.  EDHF -- are there gaps in the pathway?

Authors:  G Edwards; A H Weston
Journal:  J Physiol       Date:  2001-03-01       Impact factor: 5.182

8.  Shear stress regulates the endothelial Kir2.1 ion channel.

Authors:  Jeff H Hoger; Victor I Ilyin; Scott Forsyth; Anne Hoger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

9.  Large vasodilatations in skeletal muscle of resting conscious dogs and their contribution to blood pressure variability.

Authors:  A Just; C Schneider; H Ehmke; H R Kirchheim
Journal:  J Physiol       Date:  2000-09-15       Impact factor: 5.182

10.  Characterization of a charybdotoxin-sensitive intermediate conductance Ca2+-activated K+ channel in porcine coronary endothelium: relevance to EDHF.

Authors:  Rostislav Bychkov; Matthew P Burnham; Gillian R Richards; Gillian Edwards; Arthur H Weston; Michel Félétou; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.